Xspray-logo-white
  • Home
  • About us
    • Business model
    • Our history – a timeline
    • Board of Directors & Board committees
    • Management
  • Technology
  • Pipeline
  • Media
  • Contact
  • Investors
  • en en
    • sv sv
  • Investors
    • Share information
      • Analysts
      • Trading information
      • Ownership structure
    • Financial calendar & Events
    • Financial reports
      • ESEF report
    • Prospectus
    • Press releases
    • Corporate governance
      • Corporate Structure
      • General meetings
      • Corporate Governance Reports
      • Nomination committee
      • Board of Directors & Board committees
      • Management
      • Accounting principles
      • Internal control & Risk management
      • Auditor
      • Articles of association
      • Renumeration

Press releases

All press releases Regulatory

Press release 2021-08-06

Xspray Pharma has initiated studies with generic version of dasatinib, HyNap-Dasa ANDA

Regulatory press release 2021-08-06

Xspray Pharma publishes interim report Q2 , January – June 2021

Regulatory press release 2021-07-28

Xspray Pharma announces achievement of bioequivalence compared with reference product from bioequivalence study with HyNap-Dasa 505(b)(2)

Press release 2021-06-28

All participants in Xspray Pharma’s study have received their dose of the improved version of dasatinib

Press release 2021-06-23

Xspray Pharma’s two incentive programs are fully subscribed

Press release 2021-06-10

Xspray Pharma commences study with improved version of dasatinib

Regulatory press release 2021-05-20

Bulletin from the annual general meeting of Xspray Pharma AB (publ)

Regulatory press release 2021-05-06

Xspray Pharma publishes Interim Report Q1, January – March 2021

Regulatory press release 2021-04-20

Notice of annual general meeting of Xspray Pharma AB (publ)

Press release 2021-04-08

Xspray Pharma announces update of its improved version of dasatinib

Show more

Subscribe

  • Submit to our press releases and get an email every time we publish a press release or report on our website.
  • When clicked on Send I agree that my personal information will be saved. Read more
  • This field is for validation purposes and should be left unchanged.

IR contact

Kerstin Hasselgren, Chief Financial Officer

+46 (0)70 311 16 83

info@xspray.com

Xspray-logo-white

Xspray Pharma AB Råsundavägen 12 169 67 Solna

+46 (0)8 730 37 00 info@xspraypharma.com